111 related articles for article (PubMed ID: 38778687)
21. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy vs. cytoreductive surgery alone for intrahepatic cholangiocarcinoma with peritoneal metastases: A retrospective cohort study.
Feng F; Gao Q; Wu Y; Liu C; Yu Y; Li B; Chu K; Yi B; Cheng Q; Jiang X
Eur J Surg Oncol; 2021 Sep; 47(9):2363-2368. PubMed ID: 34119376
[TBL] [Abstract][Full Text] [Related]
22. [Construction and evaluation of a nomogram for predicting the prognosis of patients with colorectal cancer with peritoneal carcinomatosis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
An SL; Ji ZH; Li XB; Liu G; Zhang YB; Gao C; Zhang K; Zhang XJ; Yan GJ; Yan LJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):434-441. PubMed ID: 37217351
[No Abstract] [Full Text] [Related]
23. [Efficacy of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei].
Lei ZY; Ding BH; Wu QY; Luo JL; Li Z; Wang T; Wang YS; Chen YX; Huang LF; He JF; Yang XS; Guan TP; Ruan Q; Wang JH; Tang HS; Wang J; Cui SZ
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Dec; 26(12):1179-1186. PubMed ID: 38110280
[No Abstract] [Full Text] [Related]
24. Impact of intra-operative factors upon peri-operative outcomes in women undergoing hyperthermic intraperitoneal chemotherapy for gynecologic cancer.
Chichura A; Chambers LM; Costales AB; Yao M; Gruner M; Morton M; Rose PG; Vargas R; Michener CM; Debernardo R
Gynecol Oncol; 2021 Apr; 161(1):194-201. PubMed ID: 33468319
[TBL] [Abstract][Full Text] [Related]
25. HIPEC plus EPIC paclitaxel for maximal perioperative treatments of advanced epithelial ovarian cancer. Long-term results of a pilot study.
Sugarbaker PH; Stuart OA
Surg Oncol; 2020 Dec; 35():441-446. PubMed ID: 33039850
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study.
Beeharry MK; Zhu ZL; Liu WT; Yao XX; Yan M; Zhu ZG
BMC Cancer; 2019 Sep; 19(1):932. PubMed ID: 31533660
[TBL] [Abstract][Full Text] [Related]
27. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
28. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of primary peritoneal serous carcinoma: Results of a Chinese retrospective study.
Sun JH; Ji ZH; Peng KW; Wu HT; Zhang Q; Yonemura Y; Li Y
Int J Hyperthermia; 2016 May; 32(3):289-97. PubMed ID: 26982735
[TBL] [Abstract][Full Text] [Related]
29. Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
Gruner M; Chambers LM; Yao M; Chichura A; Morton M; Costales AB; Horowitz M; Rose PG; Debernardo R; Michener CM
Gynecol Oncol; 2021 Sep; 162(3):645-651. PubMed ID: 34247768
[TBL] [Abstract][Full Text] [Related]
30. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
Quénet F; Elias D; Roca L; Goéré D; Ghouti L; Pocard M; Facy O; Arvieux C; Lorimier G; Pezet D; Marchal F; Loi V; Meeus P; Juzyna B; de Forges H; Paineau J; Glehen O;
Lancet Oncol; 2021 Feb; 22(2):256-266. PubMed ID: 33476595
[TBL] [Abstract][Full Text] [Related]
31. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
[TBL] [Abstract][Full Text] [Related]
32. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial.
Yang XJ; Huang CQ; Suo T; Mei LJ; Yang GL; Cheng FL; Zhou YF; Xiong B; Yonemura Y; Li Y
Ann Surg Oncol; 2011 Jun; 18(6):1575-81. PubMed ID: 21431408
[TBL] [Abstract][Full Text] [Related]
33. Combined Prophylactic Hyperthermic Intraperitoneal Chemotherapy and Intraoperative Radiotherapy for Localized Gastroesophageal Junction and Gastric Cancer: A Comparative Nonrandomized Study.
Bazarbashi S; Badran A; Gad AM; Aljubran A; Alzahrani A; Alshibani A; Alrakaf R; Elhassan T; Alsuhaibani A; Elshenawy MA
Ann Surg Oncol; 2023 Jan; 30(1):426-432. PubMed ID: 36042103
[TBL] [Abstract][Full Text] [Related]
34. Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy.
Newhook TE; Agnes A; Blum M; Estrella JS; Das P; Ho L; Ajani JA; Minsky BD; Mansfield P; Badgwell BD
Ann Surg Oncol; 2019 May; 26(5):1394-1400. PubMed ID: 30680477
[TBL] [Abstract][Full Text] [Related]
35. Factors Associated with Resection and Survival After Laparoscopic HIPEC for Peritoneal Gastric Cancer Metastasis.
White MG; Kothari A; Ikoma N; Murphy MB; Song S; Ajani J; Mansfield P; Badgwell B
Ann Surg Oncol; 2020 Dec; 27(13):4963-4969. PubMed ID: 32648181
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: A meta-analysis of randomized controlled trials.
Granieri S; Bonomi A; Frassini S; Chierici AP; Bruno F; Paleino S; Kusamura S; Germini A; Facciorusso A; Deraco M; Cotsoglou C
Eur J Surg Oncol; 2021 Nov; 47(11):2757-2767. PubMed ID: 34001385
[TBL] [Abstract][Full Text] [Related]
37. Risk factors of acute renal impairment after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chen CY; Chang HY; Lu CH; Chen MC; Huang TH; Lee LW; Liao YS; Chen VC; Huang WS; Ou YC; Lung FC; Wang TY
Int J Hyperthermia; 2020; 37(1):1279-1286. PubMed ID: 33198563
[TBL] [Abstract][Full Text] [Related]
38. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
39. Prognostic Analysis of Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: a Propensity Score-Matched Analysis.
Liu L; Zheng L; Liu S; Zhang M; Zhang S; Jiang Z; Qin C; Wang D
J Gastrointest Surg; 2023 Nov; 27(11):2297-2307. PubMed ID: 37715013
[TBL] [Abstract][Full Text] [Related]
40. High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy.
Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liu Z; Zheng Z; Chen H; Wang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X
BMC Cancer; 2021 Jan; 21(1):41. PubMed ID: 33413223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
